Trials that use: Multiplicity adjustment
New to this method? Read the tutorial →
20,317 results
- Soluble Epoxide Hydrolase Inhibition and Insulin Resistance: Complete Statistical AnalysisIndependent statistical analysis of Soluble Epoxide Hydrolase Inhibition and Insulin Resistance: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03486223).
- SolyxIndependent statistical analysis of Post Market Study Of Single Incision Sling Versus Transobturator Sling for Stress Urinary Incontinence: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- SOM230Independent statistical analysis of Pasireotide LAR in Severe Polycystic Liver Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01670110).
- SomaSignal Tests on Medical Management and Change in Risk in Patients With Diabetes: Complete Statistical AnalysisIndependent statistical analysis of SomaSignal Tests on Medical Management and Change in Risk in Patients With Diabetes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Somatosensory Profiling in Radicular Pain Patients And it’s Correlation With Treatment Outcome: Complete Statistical AnalysisIndependent statistical analysis of Somatosensory Profiling in Radicular Pain Patients And it's Correlation With Treatment Outcome: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Somatostatin Receptor Imaging in Patients With Suspected Cardiac Sarcoidosis: Complete Statistical AnalysisIndependent statistical analysis of Somatostatin Receptor Imaging in Patients With Suspected Cardiac Sarcoidosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02546388).
- SOMBREROIndependent statistical analysis of A Study of Selexipag in Participants Who Participated in a Previous Selexipag Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- SOMEX0Independent statistical analysis of Exposure-Based Treatment for Undifferentiated Somatic Symptom Disorder: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04511286).
- SOMNOSIndependent statistical analysis of Effects of Continuous Positive Airway Pressure (CPAP) on Glucose Metabolism: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01503164).
- Somofilcon A 1-Day Multifocal Study – Real World Subjective Acceptance Study: Complete Statistical AnalysisIndependent statistical analysis of Somofilcon A 1-Day Multifocal Study - Real World Subjective Acceptance Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- SONARIndependent statistical analysis of Sentinel Node Detection in Clinical Early Stage Ovarian Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01734746).
- SongIndependent statistical analysis of Safety of New Formulation of Glatiramer Acetate: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00947752).
- Sonidegib and Lenalidomide After Stem Cell Transplant in Treating Patients With Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of Sonidegib and Lenalidomide After Stem Cell Transplant in Treating Patients With Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- SONNETIndependent statistical analysis of Combination of Lanreotide Autogel 120mg and Temozolomide in Progressive GEP-NET: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02231762).
- Sonoelastography: Ultrasound Method to Measure Liver Fibrosis: Complete Statistical AnalysisIndependent statistical analysis of Sonoelastography: Ultrasound Method to Measure Liver Fibrosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01747772).
- Sonographic Evaluation of Visceral Fat After Bariatric Surgery: Complete Statistical AnalysisIndependent statistical analysis of Sonographic Evaluation of Visceral Fat After Bariatric Surgery: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01285791).
- SONOMAIndependent statistical analysis of Post-Approval Study of the NexStent Carotid Stent System and the FilterWire EZ Embolic Protection System: SONOMA: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Sonothrombolysis in Patients With STEMI: Complete Statistical AnalysisIndependent statistical analysis of Sonothrombolysis in Patients With STEMI: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03092089).
- SonoVue®-Enhanced Ultrasound (US) Versus Unenhanced US for Focal Liver Lesion Characterization: Complete Statistical AnalysisIndependent statistical analysis of SonoVue®-Enhanced Ultrasound (US) Versus Unenhanced US for Focal Liver Lesion Characterization: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- SonoVue®-Enhanced Ultrasound Versus Unenhanced US for Focal Liver Lesion Characterization: Complete Statistical AnalysisIndependent statistical analysis of SonoVue®-Enhanced Ultrasound Versus Unenhanced US for Focal Liver Lesion Characterization: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00788697).
- SONRISAIndependent statistical analysis of Study of Neural Responses Induced by Antidepressant Effects: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02674529).
- SOPRAIndependent statistical analysis of Selinexor (KPT-330) in Older Patients With Relapsed AML: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02088541).
- SOPTIndependent statistical analysis of Sleep Optimization to Improve Glycemic Control in Adults With Type 1 Diabetes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Sorafenib and Anastrozole in Treating Postmenopausal Women With Metastatic Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Sorafenib and Anastrozole in Treating Postmenopausal Women With Metastatic Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib: Complete Statistical AnalysisIndependent statistical analysis of Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Sorafenib for Patients With Metastatic or Recurrent Esophageal and Gastroesophageal Junction Cancer: Complete Statistical AnalysisIndependent statistical analysis of Sorafenib for Patients With Metastatic or Recurrent Esophageal and Gastroesophageal Junction Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Sorafenib for the Treatment of Chronic Lymphocytic Leukemia (CLL): Complete Statistical AnalysisIndependent statistical analysis of Sorafenib for the Treatment of Chronic Lymphocytic Leukemia (CLL): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01510756).
- Sorafenib in Children and Young Adults With Recurrent or Progressive Low-Grade Astrocytomas: Complete Statistical AnalysisIndependent statistical analysis of Sorafenib in Children and Young Adults With Recurrent or Progressive Low-Grade Astrocytomas: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Sorafenib in Treating Patients Who Are Undergoing Surgery for Metastatic Kidney Cancer: Complete Statistical AnalysisIndependent statistical analysis of Sorafenib in Treating Patients Who Are Undergoing Surgery for Metastatic Kidney Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Sorafenib in Treating Patients With Advanced Anaplastic Thyroid Cancer: Complete Statistical AnalysisIndependent statistical analysis of Sorafenib in Treating Patients With Advanced Anaplastic Thyroid Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00126568).
- Sorafenib in Treating Patients With Locally Advanced or Metastatic Kidney Cancer: Complete Statistical AnalysisIndependent statistical analysis of Sorafenib in Treating Patients With Locally Advanced or Metastatic Kidney Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Sorafenib in Treating Patients With Malignant Gastrointestinal Stromal Tumor That Progressed During or After Previous Treatment With Imatinib Mesylate and Sunitinib Malate: Complete Statistical AnalysisIndependent statistical analysis of Sorafenib in Treating Patients With Malignant Gastrointestinal Stromal Tumor That Progressed During or After Previous Treatment With Imatinib Mesylate and Sunitinib Malate: primary endpoint results, effect estimate with…
- Sorafenib in Treating Patients With Metastatic or Unresectable Kidney Cancer: Complete Statistical AnalysisIndependent statistical analysis of Sorafenib in Treating Patients With Metastatic or Unresectable Kidney Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00496756).
- Sorafenib Induced Autophagy Using Hydroxychloroquine in Hepatocellular Cancer: Complete Statistical AnalysisIndependent statistical analysis of Sorafenib Induced Autophagy Using Hydroxychloroquine in Hepatocellular Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03037437).
- Sorafenib to Overcome Resistance to Systemic Chemotherapy in Androgen-independent Prostate Cancer: Complete Statistical AnalysisIndependent statistical analysis of Sorafenib to Overcome Resistance to Systemic Chemotherapy in Androgen-independent Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Sorafenib Tosylate and Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Sorafenib Tosylate and Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Sorafenib Tosylate and Gene Expression Analysis in Patients Undergoing Surgery For High-Risk Localized Prostate Cancer: Complete Statistical AnalysisIndependent statistical analysis of Sorafenib Tosylate and Gene Expression Analysis in Patients Undergoing Surgery For High-Risk Localized Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Sorafenib Tosylate in Treating Patients With Metastatic, Locally Advanced, or Recurrent Medullary Thyroid Cancer: Complete Statistical AnalysisIndependent statistical analysis of Sorafenib Tosylate in Treating Patients With Metastatic, Locally Advanced, or Recurrent Medullary Thyroid Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors: Complete Statistical AnalysisIndependent statistical analysis of Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00131911).
- Sorafenib Tosylate in Treating Patients With Recurrent Aggressive Non-Hodgkin’s Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Sorafenib Tosylate in Treating Patients With Recurrent Aggressive Non-Hodgkin's Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00131937).
- Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer: Complete Statistical AnalysisIndependent statistical analysis of Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Sorafenib Tosylate With or Without Recombinant Interferon Alfa-2b in Treating Patients With Metastatic Kidney Cancer: Complete Statistical AnalysisIndependent statistical analysis of Sorafenib Tosylate With or Without Recombinant Interferon Alfa-2b in Treating Patients With Metastatic Kidney Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Sorafenib With or Without Gemcitabine in Treating Patients With Metastatic Pancreatic Cancer: Complete Statistical AnalysisIndependent statistical analysis of Sorafenib With or Without Gemcitabine in Treating Patients With Metastatic Pancreatic Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Sorafenib-induced Hand- Foot Skin Reaction Treatment: Complete Statistical AnalysisIndependent statistical analysis of Sorafenib-induced Hand- Foot Skin Reaction Treatment: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00667589).
- Sorafenib, Docetaxel, and Cisplatin in Treating Patients With Metastatic or Advanced Gastric or Gastroesophageal Junction Cancer: Complete Statistical AnalysisIndependent statistical analysis of Sorafenib, Docetaxel, and Cisplatin in Treating Patients With Metastatic or Advanced Gastric or Gastroesophageal Junction Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Sorafenib, Gemcitabine, and Capecitabine in Treating Patients With Unresectable and/or Metastatic Kidney Cancer: Complete Statistical AnalysisIndependent statistical analysis of Sorafenib, Gemcitabine, and Capecitabine in Treating Patients With Unresectable and/or Metastatic Kidney Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- SORTIndependent statistical analysis of Survey of Osteoarthritis Real World Therapies (MK-0663-140): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01294696).
- Sound Check-Correlation Between Transperineal and Digital Cervical Exam in 3rd Trimester Pregnancy: Complete Statistical AnalysisIndependent statistical analysis of Sound Check-Correlation Between Transperineal and Digital Cervical Exam in 3rd Trimester Pregnancy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Sound Processing Innovations in Adult and Paediatric Cochlear Implant Recipients.: Complete Statistical AnalysisIndependent statistical analysis of Sound Processing Innovations in Adult and Paediatric Cochlear Implant Recipients.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05476328).
- Southwest Harvest for Health Vegetable Gardening Intervention: Complete Statistical AnalysisIndependent statistical analysis of Southwest Harvest for Health Vegetable Gardening Intervention: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04251299).